Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Part of paid clinical trials in Fairborn, Ohio.

Sponsor
Wright State University
Study ID
NCT04036188
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Triamcinolone — DRUG
    Triamcinolone 0.1% daily
  • Vitamin D3 — DIETARY_SUPPLEMENT
    40,000 IU Vitamin D3 daily
  • Placebo — DRUG
    Placebo daily

Study Details

These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.

Key Dates

Start date
Oct 16, 2019
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Triamcinolone Cream + Vitamin D3
    This arm will continue to take Vitamin D3 at Week 16 to Week 28.
  • Placebo Comparator: Triamcinolone Cream + Placebo
    Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.

Primary Outcome Measure

Improvement in Psoriasis Area and Severity Score (PASI) from baseline [ Time Frame: Week 28 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wright State PhysiciansFairbornOhio45324-

Find similar trials in Fairborn, OH

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Wright State Physicians· Fairborn, OH

Related Studies